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γ-Aminobutyric acid type A receptors (GABAARs) mediate the majority of fast synaptic
inhibition in the central nervous system (CNS). GABAARs belong to the Cys-loop
superfamily of pentameric ligand-gated ion channels (pLGIC) and are assembled from
19 different subunits. As dysfunctional GABAergic neurotransmission manifests itself in
neurodevelopmental disorders including epilepsy and anxiety, GABAARs are key drug
targets. The majority of synaptic GABAARs are anchored at the inhibitory postsynaptic
membrane by the principal scaffolding protein gephyrin, which acts as the central
organizer in maintaining the architecture of the inhibitory postsynaptic density (iPSD). This
interaction is mediated by the long intracellular loop located in between transmembrane
helices 3 and 4 (M3–M4 loop) of the receptors and a universal receptor-binding pocket
residing in the C-terminal domain of gephyrin. In 2014, the crystal structure of the β3-
homopentameric GABAAR provided crucial information regarding the architecture of the
receptor; however, an understanding of the structure and assembly of heteropentameric
receptors at the atomic level was lacking. This review article will highlight recent
advances in understanding the structure of heteropentameric synaptic GABAARs and
how these structures have provided fundamental insights into the assembly of these
multi-subunit receptors as well as their modulation by diverse ligands including the
physiological agonist GABA. We will further discuss the role of gephyrin in the anchoring
of synaptic GABAARs and glycine receptors (GlyRs), which are crucial for maintaining
the architecture of the iPSD. Finally, we will also summarize how anti-malarial artemisinin
drugs modulate gephyrin-mediated inhibitory neurotransmission.
Keywords: GABAA receptors, gephyrin, diazepam, GABA, PIP2, artemisinin, Cryo-EM, inhibitory
neurotransmission
INTRODUCTION
Complex macromolecular interplays at excitatory and inhibitory synapses contribute in a
fundamental way to the incredible functional capabilities of the human brain. Inhibition in the
central nervous system (CNS) is mediated by key members of the Cys-loop receptor superfamily,
in particular, the γ-aminobutyric acid type A receptors (GABAARs), and, to a smaller extent,
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the glycine receptors (GlyRs). Synaptic GABAARs are pentameric
ligand-gated ion channels (pLGICs) mainly composed of two α,
two β and a single γ subunit, which are selected from a diverse
pool of 19 different subunit types (Sigel and Steinmann, 2012).
Each subunit consists of an extracellular domain (ECD) rich
in β-sheet architecture, a four α-helical bundle transmembrane
domain (TMD) and two intracellular, unstructured loops,
the short M1–2 and the long M3–4 loop, connecting these
helices. The ECDs harbor the sites for the natural agonist
GABA and drugs, in particular the benzodiazepines, while
the binding site for allosteric modulators such as endogenous
neurosteroids reside in the TMD (Miller and Aricescu, 2014;
Laverty et al., 2017; Miller et al., 2017; Phulera et al., 2018;
Zhu et al., 2018).
The majority of synaptic GABAARs, as well as GlyRs,
are recruited to and anchored at the inhibitory postsynaptic
membrane by the principal scaffolding protein gephyrin
(Kirsch et al., 1991; Kneussel et al., 1999). This multi-
domain protein consists of two terminal domains; the
N-terminal G domain (GephG) and the C-terminal E domain
(GephE), which are connected by a highly unstructured
linker region (Kirsch et al., 1991; Prior et al., 1992; Schwarz
et al., 2001; Kim et al., 2006; Sander et al., 2013). The
interaction of gephyrin with postsynaptic receptors is
mediated by a continuous segment within the large intracellular
M3–4 loop and a universal receptor-binding pocket residing
in GephE. In addition to the interactions with inhibitory
neurotransmitter receptors, gephyrin also interacts with a
diverse set of macromolecules, thus playing an essential
role in establishing and maintaining the architecture of the
inhibitory postsynaptic density (iPSD; Tyagarajan and Fritschy,
2014; Kasaragod and Schindelin, 2018). Besides its anchoring
function, gephyrin also catalyzes the two terminal steps in
the evolutionarily conserved molybdenum cofactor (Moco)
biosynthesis pathway (Kuper et al., 2004; Kasaragod and
Schindelin, 2016), a critical active site component of almost all
Mo-containing enzymes.
Small molecules such as benzodiazepines, which target
synaptic α-subunit containing GABAARs, have been in clinical
use for decades for the treatment of neurological disorders
(for a detailed review see Rudolph and Knoflach, 2011).
Since dysfunctional inhibitory neurotransmission triggered by
defects residing in either the receptors or gephyrin has
been implicated in a diverse set of neurodevelopmental
disorders including anxiety and epilepsy (Agarwal et al.,
2008; Hales et al., 2013; Dejanovic et al., 2014, 2015), these
macromolecules may be suitable targets of future structure-based
drug discovery processes.
In this review article, we will highlight recent advances in
the structural elucidation of heteromeric GABAARs and how
these structures have helped us to understand the assembly
and also regulation of these ion channels by diverse ligands
(Laverty et al., 2019; Masiulis et al., 2019). Besides, we will also
briefly discuss the alternative GABAAR/GlyR recruitment to the
iPSD and finally, summarize our recent contribution on the
elucidation of the modulation of inhibitory neurotransmission
by artemisinins.
STRUCTURAL INSIGHTS INTO SYNAPTIC
HETEROPENTAMERIC GABAARs
Until recently, knowledge regarding the atomic architectures of
GABAARs and their modulation by ligands was derived solely
from structural studies performed with either homopentameric
receptors or homopentameric receptor chimeras. While the
crystal structure of the β3 homopentameric GABAAR described
the architecture of the receptor for the first time (Miller and
Aricescu, 2014), studies with chimeric versions of the GABAARs
receptors provided atomic insights into the neurosteroid
(e.g., pregnanolone and pregnenolone) binding site in the TMD
and the modulation of GABAARs by these compounds (Laverty
et al., 2017; Miller et al., 2017). Nevertheless, structures of
heteropentameric receptors had remained elusive until recently,
when several independent studies (Phulera et al., 2018; Zhu et al.,
2018; Laverty et al., 2019; Masiulis et al., 2019), which were aided
by recent developments in the field of cryo-electron microscopy
(Cryo-EM), provided crucial insights into the structure of
heteropentameric receptors.
The first Cryo-EM structure of a heteromeric GABAAR,
in this case, composed of the human α1β2γ2 subunits, was
determined by Hibbs and colleagues (Zhu et al., 2018).
Subsequently, Gouaux and coworkers (Phulera et al., 2018)
solved the Cryo-EM structure of the rat α1β1γ2 heteropentamer.
Although both structures provided valuable insights into the
binding of the agonist GABA and also the modulation of
these receptors by flumazenil, which targets the benzodiazepine
binding site, these structures were somewhat incomplete with
respect to the overall architecture of the receptors. The first
study (Zhu et al., 2018) described a structure in which the
pore had collapsed due to an unusual arrangement of the
γ2-subunit (PDB: 6D6U) while the other structure (Phulera et al.,
2018) featured fragmented density in the TMD (PDB: 6DW0).
A common denominator of these structures is that they were
solved in the presence of detergents. Whereas Phulera et al.
(2018) determined the structure by using the shorter splice
variant of the γ2 subunit, it is unclear which γ2 subunit splice
variant was used by Zhu et al. (2018). In addition, for the
structural studies, Zhu et al. (2018) replaced the intracellular
loop connecting the M3–4 helices with a seven-residue artificial
linker, whereas Phulera et al. (2018) introduced a fluorescent tag
in the M3–4 loop of the γ2 subunit in addition to shortening the
M3–4 loops of the other subunits. In this review article, we will
mainly focus on the structures of the human α1β3γ2 receptor
published recently (Laverty et al., 2019; Masiulis et al., 2019)
in which full-length GABAAR subunits were used and the
structures were solved by reconstituting the receptors in discoidal
membranes (nanodiscs) composed of a double layer of lipid
molecules surrounded by a membrane scaffold protein. These
structures yielded unprecedented insights not only into the
overall architecture of heteropentameric GABAARs but also into
the binding of diverse ligands including the agonist GABA.
Finally, these structures also demonstrated howmembrane lipids
interact with the TMD (Figures 1A–D).
All structures revealed that the subunits are arranged in an
α–β–α–β–γ arrangement in a clockwise manner when viewed
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FIGURE 1 | Structures of heteropentameric γ-aminobutyric acid type A receptors (GABAARs). (A) Side view of the overall structure of the heteropentameric
GABAAR as determined by cryo-electron microscopy (Cryo-EM). (B) Architecture of the receptor viewed from the extracellular side (top view) with the receptor
subunits in cartoon representation and the glycans in ball and stick representation. (C) View of the receptor from the intracellular side into the ion-conducting pore
(bottom view). (D) Close-up view of the glycosylation sites in the extracellular vestibule. The glycans and critical residues mediating their binding are shown in ball and
stick representation. (E) Schematic representation of the underlying principle governing the assembly of synaptic heteropentameric GABAARs. The scheme
demonstrates how glycosylation of the conserved Asn111 plays a crucial structural role in receptor assembly, which in turn also determines the order in which the
subunits are arranged. (F–L) Structures of GABAARs bound to various ligands. (F) The heteropentameric GABAAR is shown in cartoon representation along with
structurally validated ligands in space-filling representation. Enlarged views of the binding pockets of the natural agonist GABA (PDB: 6HUJ, G), the positive allosteric
modulator (PAM) diazepam (PDB: 6HUP, H–I), the competitive antagonist bicuculline (PDB: 6HUK, J), the channel blocker picrotoxin (PDB: 6HUG, K) and the lipid
PIP2 (PDB: 6I53, L). Enlarged views are shown according to the color of the box in the overall structure displayed in (F). In (F–L) all ligands and the critical residues
which mediate binding are shown in ball and stick and the protein chains in cartoon representation.
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from the extracellular side, consistent with previous biochemical
studies (Tretter et al., 1997; Baumann et al., 2002). Although the
earlier structural analyses (Phulera et al., 2018; Zhu et al., 2018)
and the more recent ones (Laverty et al., 2019; Masiulis et al.,
2019) differed in receptor subunit composition and structural
organization of the TMD, a common denominator amongst all
of them was the observation of two unique glycosylation sites in
the extracellular vestibule. These glycosylations originate from
residue Asn111 which is present in all α-subunits and hence
all heteropentameric GABAARs. In addition to several inter-
glycan interactions, Gln90 in the β-subunit mediates interactions
with these glycans via hydrogen bonds which are augmented
by a critical hydrophobic pi-pi stacking interaction with the
conserved residue Trp123 residing in the γ2 subunit (Figure 1D).
Depending on their occupancies, these glycans may have
critical implications on the assembly and subunit arrangement
in heteropentameric GABAARs. Interestingly, a recent study
(Hannan and Smart, 2018) showed that α1 homopentamer
formation is controlled by two TMD residues (Gln241 and
Ala290); if either residue is mutated (Q241W or A290W),
α1 forms functional homopentamers on the surface of HEK cells.
In addition, future research will also be required to understand
the mechanism of assembly of heterodimeric receptors and
the impact of glycosylation of Asn111 on receptor assembly.
Nevertheless, this post-translational modification (PTM) is
unique to heteropentameric GABAARs and may have critical
implications for receptor permeability while also critically
contributing to subunit composition and arrangement within
the heteropentamer (Figure 1E). In addition to this crucial
information regarding the assembly of the heteropentamers, a
series of structures of the α1β3γ2-GABAAR in complex with
diverse ligands provided valuable insights into their interactions
with these receptors as briefly described below (Figures 1F–L).
GABA
The agonist GABA only occupied the two orthosteric binding
sites created by the contribution of the principal β-subunit and
complementary α-subunit as already reported in one of the
earlier structures (Zhu et al., 2018), however, this is in contrast
to the three GABA binding sites proposed by the Gouaux group
(Phulera et al., 2018). The binding of GABA is mediated by
residues from the ‘‘aromatic box’’ created by Tyr157, Phe200,
Tyr205 from the β3-subunit and Phe65 from the α1-subunit,
which are located in the ECD at the β–α subunit interface.
The agonist is stabilized by an extensive hydrogen-bonding
network between GABA and Tyr97, Glu155 of the principal
β-subunit along with Arg67 and Thr130 from the complimentary
α-subunit. The contribution from loop-C, through Thr202 via
a hydrogen bond with the GABA carboxylate, additionally
stabilizes the agonist (PDB: 6HUJ; Figure 1G).
Diazepam
Diazepam, which acts as a positive allosteric modulator (PAMs),
has been used clinically for decades in the treatment of anxiety
disorders and also epilepsy (Rudolph and Knoflach, 2011). The
structure of the GABAAR-diazepam complex (PDB: 6HUP)
revealed that the drug molecule not only binds to the ‘‘classical
diazepam binding pocket’’ created by the principal α-subunit
and the complementary γ-subunit, but, in addition, a strong
density feature was observed in the TMD. The binding at the
ECD (Figure 1H) is mediated mainly by hydrophobic pi-pi
stacking interactions with Phe100, His102 from the principal
α-subunit and Phe77 and Tyr58 from the complementary γ-
subunit. In addition, hydrogen bonds from His102 (α-subunit)
and Asn60 (γ-subunit) augment diazepam binding at the ECD.
Strikingly, His102 has been shown to be critical for the binding
of benzodiazepine. Heteropentameric receptors composed of the
αβγ subunits and containing either the α1-α3 or α5 subunits
possess this histidine and are benzodiazepine-sensitive. In
contrast, in the α4 and α6-subunits an arginine is present at this
position and the corresponding receptors are non-responsive to
benzodiazepine (Wieland et al., 1992; Davies et al., 1998; Dunn
et al., 1999).
In contrast, the binding of diazepam in the TMD is mediated
by the M2 and M3 helices from the β-subunit as well as the
M1 helix from the α-subunit. Previous studies have proposed
this site as target area of anesthetics such as azietomidate
(Forman and Miller, 2011). The binding is mediated purely by
hydrophobic interactions involving Met286 and Phe289 from
M3 of the β-subunit as well as Leu232 and also Met236 from
M1 of the α-subunit. In addition, the drug molecule comes into
close proximity of Asn265 from the M2 helix of the β-subunit,
which, in turn, will have a direct impact on the gating properties
of the GABAAR pore (Figure 1I). The two diazepam binding
sites may provide an explanation for the biphasic potentiation of
these receptors by diazepams as observed in electrophysiological
experiments (Walters et al., 2000). Nevertheless, future research
will be required to fully understand the properties of the
secondary diazepam-binding site located in the TMD.
Bicuculline
The action of the competitive antagonist bicuculline is achieved
by its binding into the aromatic box with contributions from
loop-B and loop-C of the principal β-subunit (PDB: 6HUK).
Bicuculline is sandwiched between the aromatic Tyr157 from
loop-B of the principal β-subunit and Phe46 from the
complementary α-subunit. In addition, hydrogen bonds to the
guanidinium group of Arg67, which is also critical for agonist-
binding, mediate binding of this antagonist (Figure 1J).
Picrotoxin
The structural analyses also revealed the binding site and
blocking mechanism of GABAARs by the classical channel
blocker picrotoxin (Figure 1K). The picrotoxin-binding pocket
resides in the channel and is lined by the Leu at the 9′ position
(Leu264, Leu259 and Leu274 from the α, β and γ-subunit,
respectively) and the respective variable 2′ residues (Val257,
Ala252 and Ser267 from the α, β and γ-subunits, respectively)
of the M2 helices in each subunit. In addition, hydrogen bonds
mediated by the 6′ residues (Thr261 Thr256 and Thr271 from the
α, β and γ-subunits, respectively), with principal contributions
from the β and γ subunits, strengthen picrotoxin-binding (PDB:
6HUG).This is in contrast to the glutamate-gated chloride
channel (GluCl), in which the picrotoxin-induced channel block
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is achieved by its binding into a pocket created by the 2′-Thr and
-2′-Pro residues (Hibbs and Gouaux, 2011).
Phosphatidylinositol Phosphates
The GABAAR structure embedded in a lipid bilayer also
revealed binding sites for phosphatidylinositol 4,5 bisphosphate
(PDB: 6I53). The lipid occupies an electropositive area
exclusive to the α-subunits and its binding is mediated by
extensive hydrogen bonds from Lys312 and Arg313 from the
post-M3 loop as well as Ser388, Ser390 and Lys391 from the
pre-M4 loop with the inositol head group. PIP2 binding
is also complemented by Arg249 from the M1–2 loop
(Figure 1L). Interestingly, while Lys312 and Arg313 are
conserved in all synaptic α-subunits, the remaining residues
mediating PIP2-binding are conserved only in synaptic
α-subunits (α1–3 and α5) and not in extrasynaptic α-subunits
(α4 and α6). Thus, this specificity of synaptic GABAARs towards
PIP2 may have critical implications for receptor trafficking at
the iPSDs and on the channel gating properties as seen in the
structurally validated cases of the transient receptor potential
vanilloid 5 (TRPV5; Hughes et al., 2018), TRP mucolipin 1
(TRPML1; Fine et al., 2018) and also inward rectifier potassium
channels (Hansen et al., 2011).
ARTEMISININS—GEPHYRIN-SPECIFIC
MODULATORS OF INHIBITORY
NEUROTRANSMISSION
The central scaffolding protein gephyrin anchors a large
subset of postsynaptic GABAARs (mainly those containing the
α1-3 subunits) and also heteropentameric GlyRs, via their
β-subunit, to the iPSD. This interaction is mediated by the
universal receptor-binding pocket residing in the C-terminally
located GephE domain and the M3–4 loop of the cognate
inhibitory receptor (Maric et al., 2011). Common determinants
between GABAARs and the GlyR are the presence of an
aromatic Phe/Tyr at the first position of the core binding
pocket and a conserved Tyr at position 8 in the cognate
GABAAR subunits (Kim et al., 2006; Tretter et al., 2008,
2011; Maric et al., 2011, 2014a,b, 2015; Mukherjee et al., 2011;
Figure 2A). Both types of receptors bind to a hydrophobic
groove in GephE generated by contributions from subdomains
III and IV. Although these receptors bind to an overlapping
binding pocket and engage in similar interactions at the
N-terminus of the core-binding motif, a receptor-specific
interaction is present at the C-terminus. As could be only
derived from the crystal structures (GephE-GlyRβ-49,
Kim et al., 2006 and GephE-GABAAR α3, Maric et al.,
2014a), the Tyr at the +8 position of GABAAR α3 subunits
correspond to a Phe located at the last position of the
GlyR β-subunit.
Recently, the anti-malarial drug artemisinin and its
semi-synthetic derivatives, collectively referred to as
artemisinins, were discovered to target GABAAR signaling
by interacting with gephyrin in pancreatic cells. While one
study concluded that this interaction mediates the trans-
differentiation of glucagon-producing Tα cells into insulin-
secreting Tβ cells, thus ascribing an anti-diabetic nature to
these compounds (Li et al., 2017), subsequent studies (van der
Meulen et al., 2018; Ackermann et al., 2018) failed to reproduce
the induction of trans-differentiation in pancreas-derived cells.
Chemically, artemisinins are sesquiterpene lactones with an
unusual endoperoxide bridge. In traditional Chinese medicine,
artemisinins have been used for centuries to treat malaria
and artemisinin-based combination therapies (ACTs) such
as artesunate, the succinate derivative of artemisinin, with
lumefantrine and artemether together with mefloquine are
recommended by the World Health Organization (WHO,
2015) as standard drug regiment to treat malaria caused by
Plasmodium falciparum. In addition to their anti-parasitic
activity, artemisinins have additionally been implicated in
regulating the activity of multiple cellular pathways, including
the modulation of a variety of cancers (Crespo-Ortiz and
Wei, 2012; Tu, 2016). Despite the widespread applications
of these compounds as drugs and effectors of cellular
pathways, the molecular basis of their regulatory properties
including their target recognition mechanisms has so far
remained elusive.
Studies from our lab deciphered the molecular basis for the
interaction between gephyrin and artemisinins by determining
the first structure of a protein-artemisinin complex (Kasaragod
et al., 2019; Figure 2B). Specifically, we determined crystal
structures of GephE with the artemisinin derivatives artesunate
and artemether. The structures revealed that artemisinin-binding
is mediated by a hydrophobic pocket formed by contributions
from subdomains III and IV of GephE (Figure 2C). More
importantly, these structures revealed that these compounds
target the N-terminal region of the universal receptor-binding
pocket in GephE and inhibit important hydrophobic interactions
(368FNI370 of the GABAAR α3 subunit and 398FSI400 of the
GlyR β subunit), which represent critical determinants of
the gephyrin-receptor interactions containing the aromatic
residues at the first position of the consensus binding motif
(Figures 2D,E). Displacement isothermal titration calorimetry
(ITC) measurements and a supported membrane sheet assay
(SCMS) demonstrated that these compounds negatively
affect the gephyrin-receptor interaction. Electrophysiological
experiments revealed a significant decrease in glycinergic
currents in the presence of these compounds, with a strict
dependence on gephyrin. Furthermore, receptor and gephyrin
clustering studies displayed a strong and time-dependent
decrease in GABAAR and gephyrin cluster sizes. In addition,
our analyses also revealed a time-dependent neurotoxic effect of
these compounds, in line with previous observations of cytotoxic
effects of these compounds when administered in high doses
(Brewer et al., 1994; Wesche et al., 1994). Since artemisinins
have been shown to be capable of crossing the blood brain
barrier (Davis et al., 2003) and as dysfunctions in gephyrin-
mediated neurotransmission have been implicated in severe
neurological disorders such as Alzheimer’s disease, autism,
schizophrenia, epilepsy and also in hyperekplexia (Agarwal
et al., 2008; Fang et al., 2011; Hales et al., 2013; Dejanovic et al.,
2014, 2015), the gephyrin-artemisinin co-crystal structures
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FIGURE 2 | Alternative receptor clustering of the GABAARs by gephyrin and modulation by artemisinins. (A) Sequence alignment of the core binding motifs located
in the M3–M4 loops of the glycine receptor (GlyR) β and GABAARs α1, α2 and α3 subunits. Structurally conserved aromatic residues are highlighted with red
asterisks. The multiple sequence alignment is represented by using the ESPript server (Robert and Gouet, 2014). (B) Crystal structure of GephE in complex with the
anti-malarial drug artesunate (PDB: 6FGC). One protomer of the dimeric E domain is shown in cartoon representation, with the four subdomains (indicated by
Roman numerals) being colored differently. The second protomer is shown in surface representation in gray. The bound artesunate is shown in space-filling
representation. (C) Enlarged view of the artesunate-binding pocket demonstrating that binding is mediated by residues present in subdomains III and IV of GephE.
The bound artesunate and residues which mediate binding are shown in ball and stick representation. (D) Superimposition of the crystal structures of GephE in
complex with artesunate (PDB: 6FGC) and the GephE-GABAAR-α3 subunit-derived peptide complex (PDB:4U90). (E) An enlarged view of the binding pocket of
artemisinin or the N-terminal end of the peptide demonstrates that artesunate inhibits critical contacts (368FNI370) between the receptor and GephE.
may serve as a starting point for future drug development
efforts against these disorders. In addition, the discovery of
the artemisinin-binding pocket may serve as the basis for the
future identification of additional cellular artemisinin-targets
via in silico approaches. This study also established artemisinins
as a tool for impairing inhibitory neurotransmission, which
could eventually help to better understand the physiology of the
human brain.
CONCLUSIONS AND FUTURE
PERSPECTIVES
Despite a plethora of high-resolution structures of GABAARs
these receptors, initially homopentameric, but recently, driven
by Cryo-EM, also heteropentameric receptors, a complete
understanding of the multiple architecture and function of
the iPSD still remains elusive. First and foremost, will be
Frontiers in Molecular Neuroscience | www.frontiersin.org 6 August 2019 | Volume 12 | Article 191
Kasaragod and Schindelin GABAA Receptors and Gephyrin
to address the lack of structures of extrasynaptic GABAARs.
The structural elucidation of such a variant will certainly
reveal whether these receptors also follow the same assembly
principle as that observed for synaptic GABAARs. Furthermore,
all currently available structural information on inhibitory
neurotransmitter receptors was determined for receptors in the
absence of any binding partners. In the context of the iPSD,
one should take into consideration that these receptors are
closely associated with scaffolding proteins such as gephyrin
(Kneussel et al., 1999) and collybistin (Kins et al., 2000;
Saiepour et al., 2010) as well as with the auxiliary subunit
GARLH (Davenport et al., 2017; Yamasaki et al., 2017).
While most receptor structures were determined by shortening
the unstructured M3–M4 loop (Miller and Aricescu, 2014;
Phulera et al., 2018; Zhu et al., 2018), the most recent studies
were performed with full-length heteropentameric GABAARs
including the native M3–M4 loop (Laverty et al., 2019; Masiulis
et al., 2019). Nevertheless, even in these latest structures,
these residues could not be resolved. At the iPSD, this
region serves as the interaction hub for intracellular binding
partners and hence the full-length heteropentameric receptors
provide the necessary framework for structural studies with
intracellular binding partners such as gephyrin and collybistin.
The elucidation of the macromolecular complexes involving
the receptors and their intracellular binding partners will
provide crucial information not only regarding the structural
organization of the intracellular loops but will also generate a
molecular understanding of receptor clustering by scaffolding
proteins at the iPSD. Hence, future research should be
directed towards achieving a holistic, high-resolution view of
the iPSD.
Another critical aspect is that, although the structure of
the GephE-GABAAR α3-derived peptide complex provides
critical information about the alternative receptor recruitment
by gephyrin, high-resolution structural data describing how
different types of GABAARs are recruited and anchored at the
iPSD is still missing. The membrane sheet assay employed to
study the inhibitory effect of artemisinins can also be adopted
to analyze these uncharacterized GABAARs as it will take into
consideration possible avidity effects triggered by the presence
of two gephyrin-binding α-subunits in the heterotrimeric
GABAARs and the oligomeric state of gephyrin as well as
membrane contributions to the gephyrin-receptor interaction.
With respect to the function of gephyrin, crucial information
regarding the mechanism of the oligomeric organization of this
scaffolding protein is still missing.
Although our structures of GephE-artemisinin complexes
provide valuable insights into the modulation of inhibitory
neurotransmission by gephyrin, multiple aspects of the
regulation still remain to be deciphered; (a) What are possible
effects of artemisinins on presynaptic terminals? (b) How
does the balance of inhibitory and excitatory neurotransmission
counteract the administration of artemisinins in human patients?
(c) Are artemisinin metabolites equally potent as their parental
compounds in modulating inhibitory neurotransmission?
Although our structures can be used for the development of
gephyrin-specific regulators of neurotransmission, one has to
bear in mind that artemisinins influence a variety of cellular
pathways possibly targeting multiple proteins. Thus, future
structure-based drug design studies to optimize this lead
compound with the aim of increasing its specificity towards
gephyrin should be conducted. At the same time, structures of
these compounds with other cellular targets would be desirable
to better understand the molecular mechanism underlying
target recognition and the pharmacological action of these
anti-malarials.
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